Atovaquone 750mg/5ml oral suspension sugar free
Requires a prescription from a doctor or prescriber
Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Atovaquone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Atovaquone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
6 branded products available
MHRA licensed products
View all licensed products for Atovaquone on the MHRA register
Wellvone 750mg/5ml oral suspension
Atovaquone 750mg/5ml oral suspension sugar free
Atovaquone 750mg/5ml oral suspension sugar free
Atovaquone 750mg/5ml oral suspension sugar free
Atovaquone 750mg/5ml oral suspension sugar free
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
2.25 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 14 · Randomised trials: 8 · 1992–2026
Showing the 50 most relevant studies, sorted by most relevant.
Henry M. Staines, Rebekah Burrow, Beatrix Huei-Yi Teo, et al.
Journal of Antimicrobial Chemotherapy, 2017
- Proguanil
- Drug Combinations
- Mutation
Hiromi Nakato, Roberto Vivancos, Paul Hunter
Journal of Antimicrobial Chemotherapy, 2007
- Antimalarials
- Proguanil
- Drug Combinations
Gemma L. Nixon, Darren Moss, Alison E. Shone, et al.
Journal of Antimicrobial Chemotherapy, 2013
- Antimalarials
- Proguanil
- Drug Combinations
S Looareesuwan, Jeffrey D. Chulay, Craig J. Canfield, et al.
American Journal of Tropical Medicine and Hygiene, 1999
- Antimalarials
- Proguanil
- Drug Combinations
K. Andrejko, Romana C Mayer, S. Kovacs, et al.
Travel medicine and infectious disease, 2019
Keith Chirgwin, Richard Hafner, Catherine Leport, et al.
Clinical Infectious Diseases, 2002
- Acquired Immunodeficiency Syndrome
- Acute Disease
- Antiprotozoal Agents
Jelmer Savelkoel, K. H. Binnendijk, R. Spijker, et al.
Travel medicine and infectious disease, 2017
Thomas M. Ashton, Emmanouil Fokas, Leoni A. Kunz‐Schughart, et al.
Nature Communications, 2016
- Tumor Hypoxia
- Antimalarials
- Biguanides
Marco Fiorillo, Rebecca Lamb, Herbert B. Tanowitz, et al.
Oncotarget, 2016
- Antimalarials
- Antineoplastic Agents
- Oxidative Phosphorylation
Christine Colby, SL McAfee, Robert Sackstein, et al.
Bone Marrow Transplantation, 1999
- Pneumocystis
- Antifungal Agents
- Immunosuppression Therapy
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
2.2 to 3.2 days
Mechanism
The mechanism of action against Pneumocystis carinii has not been fully elucidated.
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
47%
Half-life
2.2 to 3.2 days
Protein binding
99.9%
Volume of distribution
0.17 L/kg
Metabolism
Elimination
0.6%
Clearance
5.5 ml/min
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 369 interactions
Rash has also been reported after overdose.
How the body processes this drug — absorption, distribution, metabolism, and elimination
Without food, the bioavailability is 23%.
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC P01AX06
ATC P01BB51
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Atovaquone
Additional database identifiers
Drugs Product Database (DPD)
8317
ChemSpider
10482034
BindingDB
16301
PDB
AOQ
ZINC
ZINC000116473771
GenBank Gene Database
M99416
GenBank Protein Database
2978420
UniProt Accession
CYB_PLAFA
GenBank Gene Database
CR382398
GenBank Protein Database
46362265
UniProt Accession
PYRD_PLAF7
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2867
GenAtlas
DHODH
GeneCards
DHODH
GenBank Gene Database
M94065
GenBank Protein Database
555594
Guide to Pharmacology
2604
UniProt Accession
PYRD_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q418179), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.